


Micro- and Nanotechnologies- Based Product Development

EDITED BY

Neelesh Kumar Mehra

Arvind Gulbake



First edition published 2022
by CRC Press
6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742

and by CRC Press
2 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN

© 2022 Taylor & Francis Group, LLC

CRC Press is an imprint of Taylor & Francis Group, LLC

Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, access www.copyright.com or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. For works that are not available on CCC please contact mpkbookspermissions@tandf.co.uk

Trademark notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Names: Mehra, Neelesh Kumar, editor. | Gulbake, Arvind, editor.

Title: Micro and nanotechnologies based product development / edited by Neelesh Kumar Mehra and Arvind Gulbake.

Description: First edition. | Boca Raton : CRC Press, 2022. | Includes bibliographical references and index.

Identifiers: LCCN 2021011182 | ISBN 9780367488451 (hardback) | ISBN 9781032050720 (paperback) | ISBN 9781003043164 (ebook)

Subjects: MESH: Nanostructures | Drug Delivery Systems | Drug Development | Nanotechnology | Microtechnology

Classification: LCC RM301.25 | NLM QT 36.5 | DDC 615.1/9—dc23

LC record available at <https://lccn.loc.gov/2021011182>

ISBN: 9780367488451 (hbk)

ISBN: 9781032050720 (pbk)

ISBN: 9781003043164 (ebk)

DOI: 10.1201/9781003043164

Typeset in Times
by codeMantra

Contents

Preface.....	vii
Editors.....	ix
List of Contributors.....	xi

SECTION A Introduction

Chapter 1 Micro- and Nanotechnology Approaches: Concepts and Applications	3
<i>Bhavana Valamla, Pradip Thakor, Neelesh Kumar Mehra, Arvind Gulbake, and Satish Shilpi</i>	
Chapter 2 Formulation by Design (FbD): An Emerging Approach to Design Vesicular Nanocarriers	15
<i>Shiv Kumar Prajapati, Payal Kesharwani, Nishi Mody, Ankit Jain, and Swapnil Sharma</i>	
Chapter 3 Thermally Responsive Externally Activated Theranostics (TREAT) for On-Demand Multifunctional Drug Delivery Systems	33
<i>Renuka Khatik, Aakanchha Jain, and Faheem Hyder Pottoo</i>	
Chapter 4 C ₆₀ -Fullerenes as an Emerging Cargo Carrier for the Delivery of Anti-Neoplastic Agents: Promises and Challenges	49
<i>Nagarani Thotakura and Kaisar Raza</i>	

SECTION B Bioactive Delivery Systems

Chapter 5 Pharmaceutical and Biomedical Applications of Multifunctional Quantum Dots	65
<i>Devesh Kapoor, Swapnil Sharma, Kanika Verma, Akansha Bish, Yashu Chourasiya, Mayank Sharma, and Rahul Maheshwari</i>	
Chapter 6 PLGA-Based Micro- and Nano-particles: From Lab to Market	83
<i>Akash Chaurasiya, Parameswar Patra, Pranathi Thathireddy, and Amruta Gorajiya</i>	
Chapter 7 Targeted Lipid-Based Nanoparticles for Nucleic Acid Delivery in Cancer Therapy.....	95
<i>Prashant Upadhaya, Swapnil Talkar, Vinod Ghodake, Namrata Kadwadkar, Anjali Pandya, Sreeranjini Pulakkat, and Vandana B. Patravale</i>	
Chapter 8 Formulation Strategies for Improved Ophthalmic Delivery of Hydrophilic Drugs.....	115
<i>Arehalli Manjappa, Popat Kumbhar, John Disouza, Suraj Pattekari, and Vandana B. Patravale</i>	
Chapter 9 Metal Nanoparticles as a Surrogate Carrier in Drug Delivery and Diagnostics	139
<i>Sushama Talegaonkar, Debopriya Dutta, Namita Chaudhary, Surya Goel, and Ruchi Singh</i>	
Chapter 10 Resealed Erythrocytes: A Biological Carrier for Drug Delivery.....	163
<i>Satish Shilpi, Kapil Khatri, Umesh Dhakad, Neelesh Kumar Mehra, and Arvind Gulbake</i>	

Chapter 11	Nanostructured Hydrogel-Based Biosensor Platform	177
	<i>Anand Singh Patel and Keerti Jain</i>	
Chapter 12	Multifunctional Carbon Nanotubes in Drug Delivery	187
	<i>Anamika Sahu Gulbake, Ankit Gaur, Aviral Jain, Satish Shilpi, Neelesh Kumar Mehra, and Arvind Gulbake</i>	
 SECTION C Product Development, Toxicity and Scale-Up		
Chapter 13	Liposomal-Based Pharmaceutical Formulations – Current Landscape, Limitations and Technologies for Industrial Scale-Up	209
	<i>Radha Rani, Neha Raina, Azmi Khan, Manupriya Choudhary, and Madhu Gupta</i>	
Chapter 14	Impact and Role of Stability Studies in Parenteral Product Development	225
	<i>Mohammed Asadullah Jahangir, Syed Sarim Imam, and Jayamanti Pandit</i>	
Chapter 15	Reverse Engineering in Pharmaceutical Product Development	235
	<i>Rishi Paliwal, Aanjaneya Mamgain, Rameshroo Kenwat, and Shivani Rai Paliwal</i>	
Chapter 16	Role of Polymers in Formulation Design and Drug Delivery	243
	<i>Satish Shilpi, Umesh Dhakad, Rajkumari Lodhi, Sonal Dixit, Kapil Khatri, Neelesh Kumar Mehra, and Arvind Gulbake</i>	
Chapter 17	Drug Delivery Systems for Targeting Blood Brain Barrier: Examples of nanomedicines for the treatment of neurodegenerative diseases	257
	<i>Iara Baldim, Adriana M. Ribeiro, João Dias-Ferreira, Wanderley P. Oliveira, Francisco M. Gama, and Eliana B. Souto</i>	
Chapter 18	Validation, Scale-Up and Technology Transfer in Product Development	269
	<i>Ankit Gaur, Anamika Sahu Gulbake, Neelesh Kumar Mehra, and Arvind Gulbake</i>	
Chapter 19	Nanotoxicology: Safety, Toxicity and Regulatory Considerations	285
	<i>Raja Susmitha, Mounika Gayathri Tirumala, Mohd Aslam Saifi, and Chandraiah Godugu</i>	
Index		305

15 Reverse Engineering in Pharmaceutical Product Development

Rishi Paliwal, Aanjaneya Mamgain, and Rameshroo Kenwat
Indira Gandhi National Tribal University

Shivani Rai Paliwal

Guru Ghasidas Vishwavidyalaya (A Central University)

CONTENTS

Abbreviations	235
15.1 Introduction	235
15.2 Pharmaceutical Reverse Engineering in Formulation Development.....	236
15.2.1 Why to Reverse the Pharmaceutical Product Development Process.....	236
15.2.2 How to Reverse the Pharmaceutical Product Development Process.....	236
15.2.3 Common Analytical Methods for Reverse Pharmaceutical Engineering	237
15.3 Reverse Pharmaceutical Engineering for Generic Product Development.....	238
15.3.1 Reverse Engineering of a Tablet.....	239
15.3.2 Reverse Engineering of a Capsule.....	239
15.3.3 Reverse Engineering of Lipid Emulsion.....	239
15.3.4 Reverse Engineering of Ocular Product.....	240
15.3.5 Reverse Engineering of a Depot Microsphere Formulation.....	240
15.4 Reverse Pharmaceutical Engineering of Herbal Product.....	240
15.5 Reverse Engineering for Stability Testing of Newer Drugs	240
15.6 Conclusion and Future Prospects	240
Acknowledgement	241
Conflict of Interest	241
References.....	241

ABBREVIATIONS

AAS:	Atomic absorption spectroscopy
ANDA:	Abbreviated new drug application
API:	Active pharmaceutical ingredient
FTIR:	Fourier transform infrared spectroscopy
GPC:	Gel permeation chromatography
HPLC:	High-performance liquid chromatography
NMR:	Nuclear magnetic resonance spectroscopy
Q1:	Qualitative
Q2:	Quantitative
RLD:	Reference listed drug
TEM/SEM:	Transmission electron microscopy/scanning electron microscopy
TGA:	Thermogravimetric analysis

15.1 INTRODUCTION

Reverse engineering process or also called deformation is quite common when one has to investigate the composition of an unknown product or a competitive product. In the pharmaceutical industry, it is helpful in the examination of

various steps of product development and unit operations of scale-up and in the identification of unknown or hidden properties of excipients used like impurities or functional groups, stability and degradation product and other related substances (Bansal and Koradia 2005, Bhatti, Syed, and John 2018). Reverse pharmaceutical engineering further helps in understanding the features of polymers like molecular weight distributions, degree of substitution, monomer ratio and substituent distribution (Bhatti, Syed, and John 2018).

To develop a generic product, the pharmaceutical deformation process starts even before the expiry of the patent. The reverse engineering process involves an exhaustive analysis to identify, quantify and characterise active pharmaceutical ingredient (API) and excipients of the original product (Oliveira et al. 2015). Since it is a time-consuming process, formulation scientist or reverse engineer has to start long before the patent expiry so that generic product development company is ready for submitting the details of their abbreviated new drug application (ANDA) product to the United States Food and Drug Administration (USFDA) as quickly as possible (Prašnikar and Škerlj 2006). As experienced by many formulators, reverse engineering is a